Abstract: SA-PO0638
Twelve-Month Continuous Nefecon in a Chinese Cohort with IgAN: Kinetics and Sustained Response
Session Information
- Glomerular Diseases: Clinical, Outcomes, and Therapeutics Research - Other
October 24, 2026 | Location: Exhibit Hall A, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics
Author
- Jun, Cheng, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Background
Real-world data on 12-month continuous Nefecon in Chinese IgAN are limited. We evaluated kinetics and sustained efficacy of 12-month therapy.
Methods
Single-center retrospective cohort of biopsy-proven IgA patients receiving Nefecon 16 mg/day for 12 months. UPCR, urinary RBC, and eGFR were assessed at baseline and months 3, 6, 9, and 12. Changes from baseline were analyzed using paired Wilcoxon signed-rank tests.
Results
50 IgA pateients involved.Mean age 38.6±10.5 years; 62% male. Baseline median UPCR 0.82 g/g, RBC 24.2 cells/μL, eGFR 68.8 mL/min/1.73m^2. 96% received RAS inhibitors and/or SGLT2i; 42% received concomitant immunosuppressants. UPCR declined rapidly by month 3 (−33.3%, p<<0.001), nadir at month 6 (−50.0%, p<<0.001), and remained suppressed at months 9 (−48.3%) and 12 (−47.1%, p<<0.001), with no rebound (6M vs 12M, p=0.437). RBC decreased at month 3 (−33.3%, p=0.021) and 6 (−47.6%, p=0.005), sustained at month 9 (−48.4%, p=0.009); month 12 reduction was −25.6% (p=0.051). eGFR remained stable (+1.7% at 12M, p=0.181). In eGFR 60–90 subgroup, UPCR reduction at 12M was greater (−60.0% vs −32.9% for eGFR <60). Adverse events were manageable with no increase during extended treatment.
Conclusion
In this Chinese IgAN cohort, 12-month Nefecon induced rapid, sustained proteinuria and hematuria reduction with maximal effect by month 6—earlier than phase 3 trials. Benefits were maintained through month 12 with stable eGFR, supporting sustained clinical benefit in Asians. No new safety signals emerged.